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Abstract 26 
Exercise training reduces the side effects of cancer treatments, however, the stress hormone 27 
response to acute exercise during prostate cancer (PCa) treatment is unclear. PURPOSE: To 28 
examine the effects of acute exercise on circulating cortisol, epinephrine (Epi), and norepinephrine 29 
(NE) concentrations during PCa treatment with and without androgen deprivation therapy (ADT). 30 
METHODS: Men with PCa (n=11), with PCa on ADT (n=11) and non-cancer controls (n=8) had 31 
blood samples for stress hormones collected before and immediately (0h), 2h, and 24h after 45 32 
minutes of intermittent cycling at 60% of peak wattage. RESULTS: NE increased by 385% 33 
(p<0.001) at 0h and remained elevated at 2h (p<0.05) with no group differences. Overall, cortisol 34 
significantly increased at 0h (36%, p<0.012) and then significantly decreased below baseline at 2h 35 
(-24%, p<0.001) before returning to resting levels at 24h. Cortisol levels during ADT were 32% 36 
lower than PCa (p=0.006) with no differences vs. controls. Epi increased immediately after 37 
exercise more in controls (817%, p<0.001) than with ADT (700%) and PCa (333%) patients and 38 
both cancer groups absolute levels were attenuated relative to controls (ADT: -54%, PCa: -52%, 39 
p=0.004). CONCLUSIONS: Compared with age-matched controls, PCa and ADT patients 40 
exhibited similar stress hormone responses with acute exercise for NE and cortisol but an 41 
attenuated EPI response that suggests altered adrenal function. Future studies should examine the 42 
physical stress of multiple exercise bouts to verify these findings and to explore the functional 43 
hormonal effects, such as immune and metabolic responses, during cancer treatment.  44 
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Introduction 45 
Prostate cancer (PCa) is the most commonly diagnosed cancer in men in the United States, 46 
accounting for approximately 20% of all new diagnoses and is the 3rd leading cause of cancer 47 
mortality 1. Prostate tumors are commonly treated with surgery, radiation, and androgen 48 
deprivation therapy (ADT), with the latter in particular being associated with a number of adverse 49 
effects including loss of muscle mass and increased fat mass 2, insulin resistance and frailty 3, and 50 
ultimately a reduced quality of life 4. 51 
Over the past decade, exercise training during PCa treatment has been shown to be safe 52 
and effective in mitigating some side effects from PCa and ADT. Specifically, muscle strength, 53 
cardiorespiratory fitness, and physical function have consistently been shown to improve with 54 
exercise training 5, 6, while other traits (i.e. body composition) have demonstrated more variable 55 
responses 7-9. As such, many organizations now recommend moderate intensity exercise as a 56 
complementary therapy to PCa treatment 10, 11. However, there is limited data available on the 57 
endocrine response, specifically the stress hormones, following acute exercise in these patients. 58 
Given the importance of these hormones in health and exercise metabolism, it is important to 59 
understand the responses to ensure exercise is beneficial to all body systems and to better optimize 60 
exercise prescription. 61 
Epinephrine (Epi), norepinephrine (NE), and cortisol are products of the adrenal gland and 62 
sympathetic nervous system activity with wide ranging effects that influence metabolism, body 63 
composition, and immune system function. Stress hormone release with exercise is intensity and 64 
duration-dependent in healthy individuals, with robust increases in circulating levels occurring 65 
when 30 minutes of exercise above 50-70% of maximal oxygen uptake is performed 12. During 66 
PCa treatment, limited data on the stress hormone response to exercise exist. We are aware of only 67 
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1 study that showed cortisol levels were unchanged after both acute resistance exercise and 68 
resistance training while on ADT 13 and no reports of the exercise-induced response of Epi and 69 
NE. However, breast cancer (BCa) survivors have shown altered substrate utilization, reduced 70 
blood lactate levels, 14, 15 and attenuated Epi and cortisol responses after acute exercise relative to 71 
controls 16, which is a potential mechanism for differences in substrate utilization. While BCa is a 72 
different type of cancer, these tumors are also hormone-dependent and provide insight to the 73 
potential stress hormone response to acute exercise during PCa treatment. 74 
While the stress hormone response to exercise is unclear in PCa patients, there is evidence 75 
of interactions between the hypothalamic-pituitary-adrenal (HPA) and hypothalamic-pituitary-76 
gonadal (HPG) axes in other populations 17, with chronic activation of the stress systems leading 77 
to decreased production of sex and growth hormones 18. Excess glucocorticoid production due to 78 
chronic stress leads to loss of lean mass and increases in visceral adiposity and insulin resistance, 79 
potentially exacerbating these symptoms already associated with ADT. Regarding stress in PCa 80 
patients, 30% of men are classified as clinically distressed prior to treatment 19 while 25% 81 
experience high anxiety post-diagnosis 20 and have greater psychological stress levels than non-82 
cancer controls 21. Chronic stress has immunosuppressive effects 22 and increases tumor growth 23, 83 
with NE specifically increasing prostate tumor migration 24. Conversely, reducing cortisol levels 84 
enhanced natural killer cell activity 25. Although the stress of cancer diagnosis and treatment is 85 
likely multi-factorial (e.g. psychological and physical), elevated anxiety and stress hormone 86 
release may promote a pro-oncogenic environment that has possible implications on long-term 87 
prognosis.  88 
With a potentially elevated psychological stress levels, the addition of exercise may 89 
actually amplify activation of the stress hormone axes, possibly having negative consequences for 90 
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PCa patients. Current exercise oncology guidelines are based on recommendations for older adults 91 
10 and do not adequately consider the immuno-endocrine interaction during exercise 16, likely due 92 
to a lack of data. Given the key roles of these respective systems in maintaining health and physical 93 
function, a greater understanding of the stress hormone response of PCa patients during exercise 94 
is warranted to optimize exercise prescriptions while improving associated outcomes and quality 95 
of life. Moreover, the inclusion of ADT as a separate group allows for the effects of this specific 96 
treatment on the stress hormone response to exercise to be explored.  97 
Therefore, the purpose of this study was to examine the effects of acute, moderate to 98 
vigorous intensity aerobic exercise on the stress hormone response in PCa patients with and 99 
without ADT compared with non-cancer controls to gain insight into the interactions of physical 100 
and psychological stress during PCa treatment. We hypothesized that PCa treatment, independent 101 
of ADT, would have higher baseline catecholamine and cortisol levels. We also hypothesized that 102 
the physical stress of interval exercise combined with psychological stress related to cancer 103 
treatment would produce significantly higher stress hormone levels post-exercise.   104 
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Methods 105 
Participants 106 
Men diagnosed with PCa on ADT [ADT; n=11, 67 (2yr)] and not on ADT [PCa; n=11, 67 107 
(2y)] were recruited from local oncology practices and support groups in Melbourne, Australia 108 
along with non-cancer controls [n=8, 64 (3y)]. ADT and PCa patients had physician-diagnosed 109 
PCa, were sedentary (not regularly exercising except for walking, and no aerobic or strength 110 
training in previous 6 months) and were screened for acute or chronic conditions that would 111 
contraindicate participation in aerobic exercise. Men on ADT were treated with luteinizing 112 
releasing hormone agonists (91%) and anti-androgen receptor (9%) medications, and needed to be 113 
on treatment for at least 3 months prior to enrolling and throughout the study. Controls had no 114 
previous cancer diagnosis or treatment but met the same inclusion criteria otherwise. All 115 
participants received medical clearance from their general practitioner prior to participation.  116 
Exclusion criteria included uncontrolled PCa, symptomatic cardiovascular disease, any 117 
conditions that caused severe pain with exertion, Type 1 diabetes, history of bone fractures, 118 
inability to engage safely in moderate exercise, or lack of medical clearance from their oncologist, 119 
urologist, general practitioner or specialist physician. The main exercise trial (visit 3) was 120 
controlled for time of day to minimize the effects of diurnal variations in hormone levels. The 121 
other tests were scheduled to minimize testing burden and aid in recruitment. 122 
Familiarization (Visit 1) 123 
 Participants were informed of the study procedures and risks and all gave their written 124 
informed consent. This project was approved by the local ethics committees at Peter MacCallum 125 
Cancer Centre, Victoria University, and Western Health and was conducted in accordance with 126 
principles set out in the Declaration of Helsinki.  127 
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For the familiarization to the graded exercise test (GXT), participants were fitted with a 128 
mask to collect expired gases and to an electronically-braked cycle ergometer (Lode, Gronigen, 129 
Netherlands). Participants rested quietly until they were comfortable to proceed and then 3 to 4 130 
submaximal stages (0 watts up to 60 or 80 watts) from the GXT were completed. All participants 131 
indicated they were comfortable with the GXT before leaving the laboratory. 132 
Preliminary Testing (Visit 2) 133 
 Participants reported to the laboratory after having fasted for at least 2 hours, not exercised 134 
in the past 24 hours, and avoided caffeine and alcohol for 12 and 48 hours, respectively. These 135 
pre-assessment guidelines were confirmed verbally and were repeated at all subsequent visits. The 136 
brief fatigue inventory (BFI) and functional assessment of cancer therapy-prostate (FACT-P) 137 
questionnaires were administered for fatigue and quality of life, respectively. Body composition 138 
was determined using dual-energy x-ray absorptiometry (Hologic, Waltham, MA, USA). Fat free 139 
mass was calculated as total mass – fat mass – bone mineral content. The scanner was calibrated 140 
daily and all scans were performed and analyzed by the same certified densitometry technician.  141 
 A GXT to determine peak oxygen consumption (VO2peak) and to set the workload for the 142 
main trial was then performed. Participants rested quietly on the cycle ergometer for 3 minutes 143 
and then completed 1 minute stages beginning at 0 watts that increased by 20 watts until volitional 144 
exhaustion. Expired gases were sampled every 15 seconds using automated gas analyzers (Moxus 145 
Modular VO2 System, AEI Technologies, Pittsburgh, PA, USA) and VO2peak was determined as 146 
the average oxygen consumption across the last minute of the test. Gas analyzers were calibrated 147 
prior to each test using known gas concentrations (21.0% O2 and 0.03% CO2, 16.0% O2 and 4.0% 148 
CO2). Heart rate was assessed continuously via 12 lead electrocardiogram (GE Case Cardiosoft 149 
v6.6 ECG Diagnostic Systems, Palatine, IL, USA) and rate of perceived (RPE) exertion using the 150 
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original Borg scale was assessed in the final 30 seconds of each stage. Following the GXT, 151 
participants completed a light cool down on the cycle ergometer and seated vital signs were 152 
monitored until heart rate and blood pressure approached resting values. 153 
Trial Protocol (Visit 3 and 4) 154 
 Approximately one week later, participants returned to the laboratory for the main testing 155 
session (visit 3). All trials commenced between 0600 and 0900. After ~10 minutes of supine rest, 156 
a venous catheter was inserted into an antecubital forearm vein for repeat blood sampling and a 157 
resting blood sample was obtained. Participants completed an acute, intermittent exercise bout 158 
consisting of 10 intervals of 3 minutes of cycling at 60% of peak wattage from the GXT followed 159 
by 1.5 minutes of passive recovery without pedaling (45 minutes total time). Expired respiratory 160 
gases were sampled throughout the trial and the last minute of each exercise stage was used to 161 
determine oxygen consumption, respiratory exchange ratios, and the percentage of exercise 162 
relative to VO2peak. Heart rate and RPE were obtained in the last 30 seconds of all stages. 163 
Additional blood samples were obtained immediately following exercise (0h) and at 2 hours (2h) 164 
post-exercise. During recovery, participants remained seated and consumed water ad libitum. 165 
Twenty-four hours after the completion of visit 3, participants returned to the laboratory for an 166 
additional post-exercise (24h) blood sample (visit 4). Participants were asked to consume an 167 
identical meal prior to visits 3 and 4, in addition to the other pre-assessment guidelines. 168 
Hormone Analysis 169 
Serum and plasma blood tubes were obtained at each time point. Serum samples were 170 
allowed to clot at room temperature for 30 minutes first and all blood samples were kept on ice 171 
until the completion of the trial. Plasma and serum were isolated, aliquoted, and stored at -80°C. 172 
Prostate specific antigen levels (R & D Systems, Minneapolis, MN, USA) and total testosterone 173 
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(Abnova, Taipei City, Taiwan) were determined at baseline only. Prostate specific antigen has a 174 
reported sensitivity of 0.030 ng/mL, an intra-assay CV of 3.0-7.2%, and an inter-assay CV of 4.8-175 
6.8%. Testosterone had a reported sensitivity of 0.05 ng/mL, an intra-assay CV of 5.0-10.0%, and 176 
an inter-assay CV of 3.7-8.4%. Cortisol, NE and Epi were assessed at all time points (Abnova, 177 
Taipei City, Taiwan). Cortisol had a sensitivity of 1.5 ng/mL, an intra-assay CV of 6.2-9.4%, and 178 
an inter-assay CV of 8.6-15.0%. Epi had a limit of detection of 0.01 pg/mL, an intra-assay CV of 179 
11.0-24.7%, and an inter-assay CV of 11.1-14.5%. NE had a limit of detection of 0.04 pg/mL, an 180 
intra-assay CV of 11.1-14.3%, and an inter-assay CV of 9.2-10.9%. All hormone analyses were 181 
performed in duplicate following manufacturer’s instructions.  182 
Hematology Analysis 183 
Complete blood counts were determined using whole blood samples from each time point 184 
(Sysmex KX-21N, Kobe, Japan). All samples were analyzed in duplicate with a maximal white 185 
blood cell difference of 0.1 cells/μL and the values were averaged. 186 
Statistical Analysis 187 
A two-way (3x4) repeated measures ANOVA with Tukey HSD post-hoc was used to assess 188 
main effects of group, time and any interaction effects on the stress hormone response. One-way 189 
ANOVA was used to assess simple effect for any significant interactions and to compare 190 
participant characteristics. Data are presented as mean (SD) and the percent changes are expressed 191 
relative to baseline. All data were analyzed using SPSS v21 (Chicago, IL, USA). Figures were 192 
made in GraphPad Prism version 7 (La Jolla, CA, USA).  193 
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Results 194 
 Participants in this study were sedentary, borderline overweight, with men on ADT having 195 
significantly greater mass, % fat, and body mass index (all p<0.05, Table 1) with no group 196 
difference for fat free mass. PCa patients were slightly more than 4 years post-diagnosis and those 197 
on ADT were approximately 3.5 years and had currently been on hormone therapy for 1.5 years at 198 
the time of study. Men on ADT had significantly lower total testosterone than PCa or controls 199 
(p<0.001) and had Gleeson scores and cancer stage scores at diagnosis that were higher than PCa 200 
(both p<0.05). Fatigue levels and co-morbidity index were similar across groups. There was a trend 201 
for reduced quality of life with ADT, as total FACT-P scores were lower than controls but this did 202 
not reach significance (p=0.102).  203 
 Absolute VO2peak values were similar, with a trend for lower relative values with ADT 204 
(p=0.060, Table 2). All exercise trials were completed at 60% of VO2peak wattage except for 2 205 
individuals (n=1 PCa and n=1 ADT) that required reductions in resistance in the later stages to 206 
allow for completion. These stages showed little change in heart rate and no change in RPE 207 
compared to earlier in the trial. The response to the exercise trial was similar across groups, with 208 
an average heart rate and VO2 that were slightly greater than 80%  of the maximum values obtained 209 
during the GXT. Respiratory exchange ratios (RER) were significantly different overall (p=0.040), 210 
with the post hoc analysis indicating a trend for men with PCa to be greater than those on ADT 211 
and controls. The exercise session was viewed as “somewhat hard,” based on an overall RPE rating 212 
of 12.6 (1.9). 213 
 For cortisol, there was no significant group x time interaction. Cortisol levels exhibited a 214 
biphasic response, significantly increasing by 36% (p=0.012) at 0h, declining to -24% of baseline 215 
at 2h (p<0.001), before returning to baseline levels at 24h (Figure 1). A main effect of group was 216 
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observed, as cortisol levels with ADT were 32% lower than PCa (p=0.006) but were not different 217 
from controls. 218 
 There was no significant group x time interaction for NE. NE significantly increased by 219 
385% at 0h (p<0.001) that remained elevated by 118% at 2h (p<0.001) but was similar to baseline 220 
by 24h (Figure 2). There were no differences between groups. 221 
 A significant group x time interaction was present for Epi (p<0.001, Figure 3). At 0h, 222 
controls demonstrated an 817% increase that was significantly greater than the changes seen with 223 
ADT (700%, p=0.008) and PCa (333%, p=0.010). No other time point was different from baseline 224 
or between groups. Due to subtle differences in baseline values and the small overall magnitude 225 
[ADT: 9.2 (10.9); PCa: 18.1 (16.1); controls: 21.1 (13.7)], the absolute change from baseline to 0h 226 
in Epi was also reported. Controls increased by 161.6 (72.8 pg/mL) but the changes with ADT at 227 
70.6 (63.8 pg/mL) and PCa at 69.6 (54.0 pg/mL) were significantly attenuated relative to controls 228 
(p=0.007).  229 
 There were no group differences for any leukocyte population at baseline (Supplemental 230 
Table 1). There were significant increases in lymphocyte and mixed cell counts at 0h compared to 231 
rest (both p<0.01) and at 0h and 2h compared to rest (all p<0.01) for neutrophils and total 232 
leukocytes.  233 
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Discussion 234 
 The aim of this preliminary study was to examine the stress hormone response after acute 235 
aerobic exercise in PCa patients with and without ADT compared to controls, which has previously 236 
not been reported. Contrary to our hypothesis, no baseline hormone differences were detected 237 
between groups, although cortisol levels were significantly reduced with ADT compared to PCa 238 
throughout the trial. All stress hormones significantly increased immediately after exercise before 239 
returning to baseline by 24h, supporting our hypothesis. However, the exercise-induced increase 240 
in Epi with PCa and ADT was attenuated, suggesting altered adrenal medulla function and partially 241 
supports observations from BCa survivors 16. More importantly, there is no evidence of an 242 
exacerbated response to physical stress from a single bout of exercise during ADT, which would 243 
have had implications on several physiological systems and the use of physical activity to mitigate 244 
the side effects of PCa treatment.  245 
A key finding is that PCa survivors with and without ADT do not have altered resting 246 
cortisol levels compared to controls. While previous work has indicated that PCa diagnosis and 247 
treatments increase anxiety and distress 19-21, this does not appear to affect circulating resting 248 
cortisol concentrations several years (~4 years) after diagnosis and completion of primary 249 
treatments. The lack of substantial differences in body composition and quality of life in the current 250 
study indirectly supports this finding. Individuals experiencing chronic stress experience smaller 251 
responses to physical or psychological challenges 26. A flatter rise in cortisol indicates HPA 252 
dysfunction that is associated with higher cardiovascular morbidity 27, suppressed immune 253 
function, and lower cancer survival outcomes 28. To explore this effect during PCa treatment, 254 
exercise-induced cortisol release exhibited a biphasic response, suggesting the HPA function is 255 
normal following a single bout of aerobic exercise. The 36% increase after aerobic exercise at 0h 256 
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in the current study contrasts the lack of change (+3.8%) reported with resistance exercise 13 and 257 
aerobic exercise (-3.3%) 16, although intensity, exercise mode, and cancer type differences likely 258 
influenced these comparisons. We found no evidence of hypercortisolism and hypogonadism 259 
working synergistically, as the cortisol response curve to acute exercise was similarly shaped and 260 
normal exercise-induced leukocytosis occurred. In fact, ADT significantly reduced cortisol levels 261 
across the trial compared with PCa alone but not controls. With ADT and complete androgen 262 
ablation, the crosstalk between the androgens and glucocorticoids may be disrupted. Previously, it 263 
has been shown that chronic stress can inhibit androgen production and there is evidence that this 264 
relationship may be bidirectional 18. For example, abiraterone acetate used to treat castrate resistant 265 
PCa decreases testosterone and also cortisol 29. In the current study, only luteinizing releasing 266 
hormone agonists and anti-androgen receptor medications were used to induce hypogonadism. We 267 
are not aware of any evidence directly showing that these medications influence circulating 268 
cortisol. However, numerous similarities between androgens and glucocorticoids and their 269 
respective receptors suggest that some forms of ADT influence the cortisol response 17.  270 
 Significant increases in catecholamine levels with acute aerobic exercise in PCa patients 271 
are a novel finding, as limited data exists for these markers during hormone-dependent cancer 272 
treatment 13, 16. Stress hormones rise exponentially with exercise intensities beyond 50-70% of 273 
maximal oxygen uptake and durations of more than 30 minutes 12, which both occurred in the 274 
current study. For NE, PCa and ADT patients demonstrated nearly 4-fold increases immediately 275 
post-exercise and levels more than twice resting levels at 2h but overall were similar to controls, 276 
indicating a normal response. The heart rate response to exercise, which is primarily under 277 
sympathetic nervous system control and NE 30, was also similar across groups. Similar NE levels 278 
between groups at rest and with exercise has potential clinical application, as chronic NE 279 
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administration increased mobility and migration of PCa tumor cell lines and metastatic progression 280 
in mice 24 and beta blocker treatment improves PCa prognosis 31. Aerobic training decreases PCa 281 
progression in mice 32, possibly due to blunted exercise-induced NE release following training. 282 
However, stress hormone release during acute exercise is necessary to mobilize natural killer cells 283 
and reduce tumor volume 33. These normal endocrine changes with exercise create an anti-tumor 284 
environment, provided the catecholamine increases are only transient. 285 
 Epi concentrations also significantly increased with exercise immediately post-exercise but 286 
returned to normal by 2h and 24h. In contrast to NE, the 0h rise in Epi was substantial less 287 
pronounced with ADT and with PCa, with 700% and 333% increases respectively, compared to 288 
controls (817%). Moreover, the absolute changes clearly show that both cancer groups experienced 289 
increases that were approximately half that seen with controls. These data are consistent with 290 
previous work where Epi increased following exercise in controls but not in BCa patients  16. 291 
Depending on the mode, repeated stress challenges may reduce the Epi response [for review see 292 
34]. For example, immobilization stress in rats failed to habituate even after 42 days 35 whereas 293 
repeated exercise exposure produced an attenuated Epi response 12. As the blunted Epi response 294 
contrasts observations from NE and cortisol, this suggests that PCa treatment may alter adrenal 295 
medulla function with exercise. The adrenal medulla produces the majority of Epi in the body 34, 296 
whereas NE is derived primarily from spillover following sympathetic nervous system activity. It 297 
is possible that NE release from the adrenal medulla is also lower in PCa and ADT patients but is 298 
being masked by NE from sympathetic spillover. As measurements in this study were made from 299 
plasma, only total hormone concentrations were available and it was not possible to determine the 300 
source. 301 
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Stress hormones have a wide range of functions, including effects on metabolism. Obese 302 
men 36 and BCa patients on endocrine therapy following chemotherapy 15 have greater rates of fat 303 
oxidation during exercise at several different intensities compared to healthy individuals. As men 304 
on ADT present with greater % fat due to the hormone therapy, lower RER values were expected. 305 
Although ADT patients had RER values that were lower than PCa, substrate utilization was similar 306 
to controls. While greater fat utilization during exercise in obese individuals and BCa patients has 307 
been previously reported, this was not the case in this study, where all groups had high 308 
carbohydrate utilization (RER values were on average slightly less than 1.0). Even though 309 
statistically significant from the other groups, an RER value of 1.05 in PCa is not likely to be 310 
clinically relevant and would not drastically alter substrate utilization as all individuals were using 311 
primarily carbohydrate during exercise. Participants were at least 2h post-prandial and refrained 312 
from caffeine and alcohol intake, but diet was not strictly controlled and carbohydrate intake prior 313 
to or the morning of the trial for PCa patients could be influencing these results. As such, these 314 
findings need to be confirmed using more rigorous dietary controls. 315 
Stress hormone concentrations returned to resting levels at 24h, signifying that exercise 316 
bouts of this fashion on consecutive days may be an option for patients. Leukocyte populations 317 
had returned to baseline levels after 24h (Supplemental Table 1) and similar immune cell 318 
mobilization and cardiovascular outputs after exercise also support this. The modest difference in 319 
RER values discussed previously may be negligible with solely carbohydrate sources. We 320 
postulate that group differences in glycogen depletion after exercise would be minimal, as this has 321 
been shown to alter stress hormone levels during exercise 37.  322 
Exercise oncology guidelines, based on recommendations for exercise in older adults, 323 
recommend 150 minutes of exercise per week, achieved through moderate intensity exercise on 324 
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most (~5) days of the week or vigorous exercise 3 days per week 10, 11. The classification of the 325 
exercise bout in the current study could be either moderate or vigorous. Participants rated the 326 
session as ‘somewhat hard’ on the Borg RPE scale, likely due to the rest intervals, whereas heart 327 
rate and VO2 were both above 80% of the peak values obtained from the GXT and is consistent 328 
with vigorous exercise 15. Our group has demonstrated previously that vigorous resistance exercise 329 
during ADT appears to be safe and may produce more favorable outcomes 8, 38 compared with 330 
trials using lower intensity 7. Regarding safety, most exercise oncology studies have been 331 
conducted post-treatment except for ADT 7-9, 13. For the current study, there were no adverse events 332 
during testing and there was only one patient (PCa group) who could not complete the exercise 333 
bout. Interestingly, this individual had recently (within 1-2 weeks) completed his radiation therapy. 334 
With n=1, this may be coincidental but supports the hypothesis that the exercise stress hormone 335 
response could be different in PCa patients undergoing active treatment. For instance, 336 
chemotherapy administered  during BCa treatment was associated with higher musculoskeletal 337 
pain, weight issues, and nausea 39, which may increase the relative exercise intensity and the 338 
corresponding endocrine response.  339 
This study has several strengths and limitations. It is the first to determine the stress 340 
hormones levels following aerobic exercise in PCa patients and provides novel information that 341 
the response to physical stress is relatively normal. We were also able to explore the specific effects 342 
of ADT. However, the small sample size requires that we designate these findings as preliminary. 343 
While our data appear promising that physical and cancer-related stress are not being compounded, 344 
these results are from a single exercise bout. Examining this response across multiple sessions may 345 
give better insight into the relationship with the stress hormone response and exercise training. 346 
Moreover, the patients were several years post-diagnosis and had been on ADT for more than a 347 
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year. Newly diagnosed patients or those recently commencing ADT may respond differently, as 348 
coping strategies to the physical changes from treatment and psychological burden may not have 349 
occurred. While most endocrine studies utilize continuous exercise, intervals were used to improve 350 
the likelihood of cancer patients being able to complete the trial by incorporating rest periods. 351 
While possibly affecting the response, this approach helped ensure that PCa and ADT patients 352 
achieved sufficient intensity and duration to stimulate sufficient stress hormone release. Lastly, 353 
despite attempts to match the participants on physical characteristics, a few differences in body 354 
composition exist that may have influenced the results. 355 
 In conclusion, this initial study using acute aerobic exercise to examine the stress hormone 356 
response during PCa treatment yielded several interesting findings, including lower overall cortisol 357 
levels with ADT and a blunted Epi response in both cancer groups. Here we show that 45 minutes 358 
of moderate to vigorous interval exercise stimulates a robust response but stress hormone levels 359 
returned to resting levels 24h, suggesting sufficient recovery from this single bout. Future 360 
directions should examine this response with micro- or meso-cycles to confirm these findings 361 
across multiple training bouts in recently diagnosed patients commencing treatment. Such 362 
approaches will allow for a more thorough analysis of the endocrine response to exercise during 363 
times of heightened psychological distress and to explore possible adrenal fatigue in PCa patients 364 
undergoing treatment. Furthermore, exploring the relationship between sex steroid ablation and 365 
low cortisol levels will allow for greater insight into the potential impact on the immune system; 366 
this is a pertinent question since both cortisol and sex steroids have been shown to impact the 367 
immune response. Collectively, this would permit improved exercise prescription that factors in 368 
additional physiological systems, leading to better use of exercise in managing the side effects of 369 
PCa treatment.  370 
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 371 
Perspectives 372 
 Exercise, particularly when performed at moderate to vigorous intensity, has demonstrated 373 
multiple benefits to cancer patients. Intense training has provided some of the most pronounced 374 
responses during ADT 5, 8, 38, but there are potential drawbacks that need be considered. Injury risk 375 
may increase and more subtle changes, such as immunosuppression or altered inflammatory 376 
responses are possible but have not yet been examined with appropriate designs. Studies that 377 
address these issues will allow for a greater understanding of the complex interactions between 378 
physiological systems that occur with exercise and cancer treatment. The ultimate goal is to 379 
provide individualized exercise prescription that takes into account a multitude of factors (e.g. 380 
treatments, time since diagnosis, comorbidities) that are currently beyond our ability to control to 381 
optimize these complementary therapies and to enhance quality of life during cancer treatment.  382 
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Figure Captions 499 
 500 
Figure 1. Cortisol levels significantly increased in response to acute, intermittent aerobic exercise 501 
during prostate cancer treatment. ADT was significantly less than PCa throughout but was not 502 
different than controls (CON). Data are represented mean (SD). Time points with different letters 503 
are significantly different from each other (p<0.05). † Indicates group difference for ADT vs. PCa 504 
(p=0.006). 505 
 506 
 507 
Figure 2. Norepinephrine (NE) levels at rest and in response to acute, intermittent aerobic exercise 508 
during prostate cancer treatment. No group differences were observed. Data are represented mean 509 
(SD). Time points with different letters are significantly different from each other (p<0.05).  510 
 511 
 512 
Figure 3. Changes in epinephrine (EPI) levels in response to acute, intermittent aerobic exercise 513 
are attenuated during prostate cancer treatment compared to controls (CON). Data are represented 514 
mean (SD). Time points with different letters are significantly different from each other (p<0.05).  515 
# Indicates CON was significantly different than PCa and ADT group at the specific time point 516 
(p<0.001). 517 
